

Introduction

T-cell receptor (TCR) based immunotherapies are becoming an important cornerstone of immuno-oncology. Complete TCR sequencing requires single-cell resolution to capture both α and β chains. There is great interest in obtaining single-cell TCR sequences from archived tumor tissue. This task requires technology that can not only retrieve single cells but also sequence degraded RNA from archived tissues samples at the single cell level. The RareCyte CyteFinder® platform provides integrated multi-parameter imaging and retrieval capabilities for identification and isolation of rare cells and microscopic regions of interest (ROI) for molecular analyses. Archer® has developed the Immunoverse™ platform of targeted Next-Generation Sequencing (NGS) assays to characterize the human immune repertoire from partially degraded RNA inputs. Combining these two technologies affords the unique potential to accelerate engineered cell-based therapeutic by sequencing TCR from individual cells.


Methods

ROIs (~40 μ m) containing 1 to 10 T-cells were isolated from fresh/frozen (OCT) melanoma or OCT and FFPE tonsil using the CyteFinder® system with CytePicker® module. In addition, single flu antigen-specific T-cells were retrieved from live cell preparations. OCT tonsil sections were stained with a 3-color panel to discriminate T-cell and B-cell zones, and OCT tumor sections were stained with a 6-color panel to identify immune infiltrate. FFPE sections were stained with a 6 color panel which guided picking from a serial section stained with only a nuclear marker. The Archer® Immunoverse™ TCR All Chains library preparation kit was used to generate libraries which were then sequenced on the Illumina NextSeq platform. The resultant library sequences were de-duplicated, error corrected, aligned to reference V, (D), J and C regions of TCRs, and assembled to identify clonotypes from α and β chains using the Archer® Analysis tool.

Figure 1. Rare cell isolation, RNA extraction and multiplexed TCR sequencing assay.

(A) Conditions tested in each experiment. (B) T-cells of interest were isolated using the CyteFinder® system with CytePicker® module. (C) RNA from T-cells were analyzed with the Immunoverse™ TCR assay for simultaneous interrogation of TCR α , β , γ and δ chains. The assay uses ligation-based molecular barcoding of reverse transcribed cDNA and subsequent multiplexed PCR. Universal primer binding sites are ligated to the variable TCR gene segment and opposing gene specific primers (GSP) are used to generate a sequencing library containing the CDR3. (D) Archer® Analysis was used for de-multiplexing, PCR de-duplication, and identification of CDR3, V, D, J and C regions on a per-molecule basis.

Experiment	Input Type	RNA QC (Status)	Lysis buffer	RNA Isolation	WTA	Tissue	# Cells	Cancer RNA	PCR 1&2 Cycling #	PCR 1&2 Extension Time (min)
2	Live single T-cell	N/A	SmartSeq (no ProK)	Agencourt Formapure	none	Flu or Jurkat	1	No	1620	3/3
3	Live single T-cell	N/A	SmartSeq (no ProK)	Agencourt Formapure	none	Flu or Jurkat	1	Yes or No	1620	3/3
3	Live single T-cell	N/A	Qiagen RNeasy (no ProK)	none	Qiagen RNeasy-G	Flu or Jurkat	1	Yes or No	1620	3/3
1	OCT Tissue ROI	none	Qiagen PKD (ProK)	Agencourt Formapure	none	Tonsil	4-1000	No	1620	3/3
1	OCT Tissue ROI	none	Qiagen PKD (ProK)	Agencourt Formapure	none	Tonsil	4-1000	No	1620	3/3
2	OCT Tissue ROI	yes	Qiagen PKD (ProK)	Agencourt Formapure	none	Melanoma	1-10	No	1620	3/3
4	OCT Tissue ROI	yes	Qiagen PKD (ProK)	Agencourt Formapure	none	Lung	1-5	No	1620	15/3
4	OCT Tissue ROI	yes	Qiagen PKD (ProK)	Agencourt Formapure	none	Lung	1-5	No	820	15/3
4	OCT Tissue ROI	yes	Qiagen PKD (ProK)	Agencourt Formapure	none	breast	1-5	No	820	15/3
1	FFPE Tissue ROI	none	Qiagen PKD (ProK)	Agencourt Formapure	none	Tonsil	~4-1000	No	1620	3/3
1	FFPE Tissue ROI	none	Qiagen PKD (ProK)	Agencourt Formapure	none	Tonsil	~4-1000	No	1620	3/3
4	FFPE Tissue ROI	yes	Qiagen PKD (ProK)	Agencourt Formapure	none	Lung	~5-10	No	1620	15/3
4	FFPE Tissue ROI	yes	Qiagen PKD (ProK)	Agencourt Formapure	Qiagen RNeasy-G	Lung	~5-10	No	820	15/3



Results

Figure 2. Transcript Detection Trends with Input Mass and RNA Preparation Method. (A) TCR transcripts were detected from RNA isolated from ROI retrieved from OCT and FFPE tonsil when processed with the Immunoverse™ TCR assay. The numbers of transcripts observed correlated with the number of isolated cells analyzed. The sample source also affected the number of observed clonotypes with more being observed in samples of RNA isolated from OCT tissue compared to FFPE. (B) Data from live T-Cell input show WTA increased the number of samples in which both α and β chains are observed, and stimulated T-cells had a lower rate of detection of both α and β chains from the same sample. This reduced number of observed chains in stimulated cells may be due to decreased expression levels (Gallegos et al., 2016 *Nat. Immunol.*)






Figure 3. α/β Chain Transcripts Detected in Optimal Cutting Temperature and FFPE Samples (A) Heat map of per-sample clonotype detection on a per-chain level. (B) Percent of samples in which both α and β chain transcripts were detected.



Results, Continued

Figure 5. Archer® Analysis was used to identify T-cell receptor clonotypes from the sequencing data. (A) Many single cell samples have more than 1 α and 1 β chains identified, likely due to PCR and/or sequencing errors. The most abundant clonotype identified per sample often only differed from the other clonotypes by a few insertions, deletions or mismatches. After applying an empirically derived frequency filter of 0.45, the number of single cell samples in which exactly 1 α and 1 β clonotype was identified increased from 0/22 (B) to 20/22 (C).




Figure 6. Previously published sequences identified in sequencing results from single T-cell trained against Flu antigen. α - β chain pairs were identified in several live T cells trained against a flu antigen and in live Jurkat cell line cells. CDR3 sequences from single flu-targeting T-cells (Blue) were found to match previously published data (Chen et al., 2017, *Cell Reports*). Other, un-published, CDR3 sequences were also found in single flu-targeting T-Cells (Black). Furthermore, single Jurkat cell line CDR3 sequences were obtained (Red) and found to match previously identified sequences (IMGT/LIGM-DB: K02777 and K02779 for α and β , respectively).

α - β Pair	TRA	TRB
Flu #1	CAGGGSQGNLIF	CASSVRSSEYQYF
Flu #2	Not Detected	CASSGRSTDTQYF
Flu #3	CAGAIGSSNTGKLIIF	CASSQYVPGRRRNIQYF
Flu #4	CAMSGGGSQGNLIF	CASSIRSTDTQYF
Flu #5	CAAGGSQGNLIF	CASSIRSSSEYQYF
Flu #6	CAGAGGSQGNLIF	CASSSTRSSETQYF
Flu #7	CAVRDGTGANNLFF	CASSHGLSSSEYQYF
Flu #8	CALSPRRQHRQTIF	CSARSGGILNEQFF
Flu #9	CAVRWGGFQGNLVC	CASSSILKQYF
Jurkat	CAVSDLEPNSSASKIIF	CASSFSTCSANYGYTF

Conclusions and Discussion

These results support the utility of the RareCyte CyteFinder® platform with CytePicker® module combined with Archer® Immunoverse™ chemistry and Archer® Analysis software for profiling RNA derived from single cell to low numbers of cells in either fresh/frozen tissue, FFPE tissue, or live cells. Using a workflow that combines RareCyte and Archer® technologies, we have identified α and β chain pairs from single T-cells isolated from OCT, live cell culture, and the Jurkat cell line.

These combined methodologies are a potentially promising lead for the future of T-cell therapies that require characterization of specific T-cell receptor sequences that target specific antigens.

References:

- Sequence and Structural Analyses Reveal Distinct and Highly Diverse Human CD8+ TCR Repertoires to Immunodominant Viral Antigens. Chen et al., 2017, *Cell Reports* 19, 569–583.
- Bolotin et al., *Nat. Methods*. 5, 380-381 (2015).
- Control of T cell antigen reactivity via programmed TCR downregulation. Gallegos et al., 2016, *Nat. Immunol.* 17(4), 379-386.
- IMGT/LIGM-DB. Giudicelli, V. et al., *Nucleic Acids Res.*, 34, D781-D784 (2006)